# Genmab A/S: overview GMAB · Nasdaq · CIK 1434265 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/gmab.md) · [Financials](/companies/gmab/financials.md) · [Filings](/companies/gmab/filings.md) · [Insiders](/companies/gmab/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2018-12-31) | FY2019 (2019-12-31) | FY (2023-12-31) | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3,025](/filings/0001558370-20-003378.md) | [5,366](/filings/0001558370-20-003378.md) | [2,390](/filings/0001434265-26-000014.md) | [3,121](/filings/0001434265-26-000014.md) | [3,720](/filings/0001434265-26-000014.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [32.3%](/filings/0001434265-26-000014.md) | [31.1%](/filings/0001434265-26-000014.md) | [28.6%](/filings/0001434265-26-000014.md) | | Net margin | % | not reported | not reported | [26.4%](/filings/0001434265-26-000014.md) | [36.3%](/filings/0001434265-26-000014.md) | [25.9%](/filings/0001434265-26-000014.md) | | Diluted EPS | $ per share | not reported | not reported | [9.58](/filings/0001434265-26-000014.md) | [17.53](/filings/0001434265-26-000014.md) | [15.37](/filings/0001434265-26-000014.md) | | Free cash flow | $m | not reported | not reported | [1,018](/filings/0001434265-26-000014.md) | [1,099](/filings/0001434265-26-000014.md) | [1,149](/filings/0001434265-26-000014.md) | - Revenue. XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers; Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers; Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gmab/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $360.8m | 13,133,131 | | Added +5,165,295 | | [Orbis Allan Gray Ltd](/funds/1663865.md) | 2026-06-30 | $312.3m | 11,368,161 | | Reduced −1,557,417 | | [ALLIANCEBERNSTEIN L.P.](/funds/1109448.md) | 2026-06-30 | $231.9m | 8,644,877 | | Reduced −912,272 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $188.6m | 6,865,000 | | Added +4,403,000 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $155.2m | 5,650,000 | | Added +1,986,750 | | [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $136.7m | 4,975,324 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $128.3m | 4,671,252 | | Added +134,687 | | [Sofinnova Investments, Inc.](/funds/1631134.md) | 2026-06-30 | $111.1m | 4,045,215 | | Added +3,292,954 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $96.6m | 3,517,850 | | Reduced −896,700 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $96.3m | 3,506,843 | | Added +1,167,411 | ## Recent filings [All 556 filings](/companies/gmab/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 11:58 ET | [6-K](/filings/0001434265-26-000138.md) | Report of a foreign private issuer, period 2026-10-23 | 0001434265-26-000138 | | 2026-10-13 | 07:50 ET | [6-K](/filings/0001434265-26-000136.md) | Report of a foreign private issuer, period 2026-10-13 | 0001434265-26-000136 | | 2026-10-07 | 12:27 ET | [6-K](/filings/0001434265-26-000134.md) | Report of a foreign private issuer, period 2026-10-07 | 0001434265-26-000134 | | 2026-10-05 | 15:28 ET | [6-K](/filings/0001434265-26-000132.md) | Report of a foreign private issuer, period 2026-10-05 | 0001434265-26-000132 | | 2026-10-02 | 13:51 ET | [6-K](/filings/0001434265-26-000129.md) | Report of a foreign private issuer, period 2026-10-02 | 0001434265-26-000129 | | 2026-09-29 | 10:40 ET | [6-K](/filings/0001434265-26-000127.md) | Report of a foreign private issuer, period 2026-09-29 | 0001434265-26-000127 | | 2026-09-24 | 14:45 ET | [6-K](/filings/0001434265-26-000125.md) | Report of a foreign private issuer, period 2026-09-24 | 0001434265-26-000125 | | 2026-09-09 | 10:43 ET | [6-K](/filings/0001434265-26-000123.md) | Report of a foreign private issuer, period 2026-09-09 | 0001434265-26-000123 | | 2026-09-09 | 17:57 ET | [6-K](/filings/0001434265-26-000120.md) | Report of a foreign private issuer, period 2026-09-08 | 0001434265-26-000120 | | 2026-09-08 | 07:47 ET | [6-K](/filings/0001434265-26-000116.md) | Report of a foreign private issuer, period 2026-09-08 | 0001434265-26-000116 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001434265-26-000014.md), filed Feb 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1434265 - Tickers: GMAB, GNMSF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 09:43 ET. No prices; not investment advice.